Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

August 7, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search